Tenofovir poses risk with didanosine.
D000225:Adenine / Q000009:adverse effects* / Q000031:analogs & derivatives*; D019380:Anti-HIV Agents / Q000008:administration & dosage* / Q000009:adverse effects; D000075202:Contraindications; D016049:Didanosine / Q000008:administration & dosage / Q000097:blood*; D004334:Drug Administration Schedule; D006801:Humans; D063065:Organophosphonates; D009943:Organophosphorus Compounds / Q000009:adverse effects*; D010195:Pancreatitis / Q000139:chemically induced; D000068698:Tenofovir
D019380:Anti-HIV Agents; D063065:Organophosphonates; D009943:Organophosphorus Compounds; D000068698:Tenofovir; D000225:Adenine; D016049:Didanosine